Krystal Biotech, Inc.
Financials
Valuation Metrics
Krystal Biotech, Inc.'s Market Cap is $9.21B. At end of 2025 it was $7.14B. Ranked #999 of 3,112 in US market (top 32%), #322 of 1,445 on NASDAQ (top 22%), #49 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.21B | US#999/3,112 Sec#49/269 |
| Revenue | $417M | US#2,432/3,112 Sec#86/269 |
| Net Income | $225M | US#1,216/3,112 Sec#43/269 |
| Total Assets | $1.40B | US#2,278/3,112 Sec#72/269 |
| Net Assets | $1.28B | US#1,598/3,112 Sec#51/269 |
| Employees | 295 | US#1,400/3,112 Sec#52/269 |
| Value | ||
| P/E | 40.95x | US#1,719/3,112 Sec#56/269 |
| P/B | 7.22x | US#2,436/3,112 Sec#179/269 |
| PEG | 0.72x | US#714/3,112 Sec#27/269 |
| P/S | 22.08x | US#2,826/3,112 Sec#149/269 |
| EV/EBITDA | 43.47x | US#2,315/3,112 Sec#74/269 |
| FCF Yield | 2.58% | US#1,842/3,112 Sec#65/269 |
| Profitability | ||
| ROE | 17.63% | US#691/3,112 Sec#41/269 |
| ROA | 16.11% | US#178/3,112 Sec#27/269 |
| Op. Margin | 42.85% | US#197/3,112 Sec#10/269 |
| Revenue Growth | 31.95% | US#471/3,112 Sec#67/269 |
| Earnings Growth | 56.53% | US#519/3,112 Sec#26/269 |
| Financial Health | ||
| Debt Ratio | 9.42% | US#99/3,112 Sec#43/269 |
| Total Debt | $9M | US#2,793/3,112 Sec#202/269 |
| FCF | $237M | US#1,263/3,112 Sec#42/269 |
| Cash | $501M | US#1,066/3,112 Sec#55/269 |
| Current Ratio | 9.46x | US#266/3,112 Sec#84/269 |
| Net Debt/EBITDA | -2.45x | US#154/3,112 Sec#10/269 |
| Performance | ||
| 1Y Return | 99.11% | US#190/3,112 Sec#58/269 |
| 1M Return | -16.66% | US#2,873/3,112 Sec#217/269 |
| From 52W High | -18.29% | US#1,617/3,112 Sec#98/269 |
| 1Y MDD | -17.34% | US#475/3,112 Sec#15/269 |
| Trading | ||
| Volume | 1,171,170 shares | US#1,348/3,112 Sec#135/269 |
| Trading Value | $368M | US#293/3,112 Sec#15/269 |
| Per Share | ||
| EPS | $7.08 | US#414/3,112 Sec#14/269 |
| BPS | $42.14 | US#543/3,112 Sec#11/269 |
Company Info
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.